ABSTRACT
Objective:To analyze the effects of the main drug resistance mutations in the integrase (IN) region on the resistance of HIV-1 CRF01_AE strains, and compare the differences with subtype B strains.Methods:Seven IN region mutations or combined mutations (T66K, F121Y, Q148K, N155H, G118R, R263K, Q148K/N155H) were selected from the HIV drug resistance database of Stanford University in the United States, and introduced to the IN region of HIV-1 B subtype infectious clone pNL4-3 and CRF01_AE infectious clone pGX002 by seamless cloning, homologous recombination and point mutation. The mutant plasmids were transfected into 293T cells for virus packaging. The culture was expanded in MT2 cells and infectious titers were detected. Half maximal inhibitory concentrations (IC 50) of four integrase inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG) and bictegravir (BIC), against 14 mutant viruses were detected and compared with the IC 50 against the wild-type viruses. Results:B subtype and CRF01_AE plasmids carrying seven IN region mutations or combined mutations were successfully constructed, and 14 recombinant viruses were packaged with an infectious titer of 10 4-10 6 median tissue culture infective dose (TCID 50)/ml. The recombinant viruses replicated efficiently in MT2 cells. The concentrations of HIV-1 p24 antigen contained in the supernatants of cell culture reached 830-2 700 ng/ml. Five mutations or combined mutations (T66K, F121Y, Q148K, N155H, Q148K/N155H) caused CRF01_AE and B subtype strains to be highly resistant to RAL and EVG, resulting in an increase in the IC 50 by 200 times and 2 000 times or more as compared with the IC 50 against the wild-type viruses. The same mutation-caused fold changes of IC 50 of RAL and EVG against CRF01_AE were significantly lower than that of subtype B ( P<0.01). Q148K/N155H mutation caused B subtype and CRF01_AE to be highly resistant to DTG and BIC, with IC 50 increased by more than 50 times. Other mutations had little effects on the sensitivity to DTG and BIC. Conclusions:Fourteen HIV-1 strains carrying seven INSTI resistance mutations based on B subtype and CRF01_AE were constructed. Five mutations resulted in high resistance to RAL and EVG, and there was a high level of cross-resistance. Resistance to RAL and EVG caused by the same mutation was higher in B subtype than in CRF01_AE. The combined mutation of Q148K and N155H was associated with greater resistance to DTG and BIC, indicating that the genetic barrier of DTG and BIC resistance was high. DTG and BIC could effectively inhibit the strains carrying INSTI resistance mutations without obvious subtype difference.
ABSTRACT
Resumen Introducción: en pacientes con virus de inmunodeficiencia humana algunos antirretrovirales afectan el perfil lipídico incrementando el riesgo cardiovascular. Hay evidencia de que los inhibidores de integrasa afectan poco al perfil lipídico. El presente estudio buscó evaluar la mejor evidencia disponible sobre cambios en lípidos de pacientes con virus de inmunodeficiencia humana que cambiaron su terapia antirretroviral a esquemas con inhibidores de integrasa. Métodos: revisión sistemática de la literatura con intención metaanalítica. A partir de la pregunta: "En pacientes mayores de 16 años con virus de inmunodeficiencia humana, los esquemas antirretrovirales que incluyen inhibidores de integrasa comparados con aquellos esquemas antirretrovirales que no los incluyen, ¿presentan cambios en el perfil lipídico?" se extrajeron palabras clave para búsqueda de la evidencia publicada entre 1997 y diciembre 2019. Se incluyeron estudios experimentales y observacionales y su calidad fue evaluada. Se realizó análisis por inhibidor de integrasa y parámetro lipídico buscándose síntesis cuantitativa de la evidencia. Resultados: se identificaron 17 estudios relevantes susceptibles de síntesis de la evidencia con un total de 5 683 pacientes. De estos, 2 878 entraron a síntesis cuantitativa. Acorde a lo encontrado, los inhibidores de integrasa presentan mejor perfil lipídico comparados a otros antirretrovirales. Dolutegravir fue el que mostró mejor perfil lipídico cuando la comparación se hizo con inhibidores de proteasa. Raltegravir tuvo mejor perfil lipídico comparándolo con inhibidores de transcriptasa inversa no análogos de nucleósidos. Conclusiones: el uso de inhibidores de integrasa es un factor relevante en el control del riesgo cardiovascular en pacientes con virus de inmunodeficiencia humana.
Abstract Introduction: some antiretrovirals affect the lipid profile in human immunodeficiency virus patients increasing their cardiovascular risk. Integrase inhibitors generate little lipid alteration. The present study evaluated the best available evidence about changes in the lipid profile in human immunodeficiency virus patients who had switch from different antiretroviral therapies to schemes with integrase inhibitors. Methods: a systematic review with meta-analytic intention was carried out. From the question "How does antiretroviral schemes with integrase inhibitors impact in lipid profile in human immunodeficiency virus patients compared to antiretroviral schemes without integrase inhibitors?" an evidence search was done. Articles from experimental and observational studies were included and the quality was evaluated. An analysis by integrase inhibitor and lipid parameters was performed. Results: 17 relevant studies were identified and 2 878 patients were included in the quantitative synthesis. According to evidence, integrase inhibitors had a better lipid profile compared to other antiretrovirals. Dolutegravir had a better metabolic profile when it was compared with protease inhibitors. Raltegravir had a better lipid profile when it was compared to non-nucleoside analog reverse transcriptase inhibitors. Conclusions: integrase inhibitors are a relevant factor for cardiovascular risk control in patients with human immunodeficiency virus.
ABSTRACT
La Guía Colombiana de práctica clínica para la atención de la infección por VIH / Sida en adolescentes y adultos incluye como primera línea de tratamiento el uso de Inhibidores de integrasa; sin embargo, no incluye recomendaciones que soporten la decisión de tratar a los pacientes controladores elite (CE). La definición de controladores elite es confusa pues varía de un estudio a otro y se desconoce si las recomendaciones de tratamiento, se pueden aplicar a los controladores de forma similar; tampoco existen mecanismos apropiados para el seguimiento sistemático de los controladores elite cuando se inicia en ellos una terapia antirretroviral. Este artículo es una revisión bibliográfica de la información disponible sobre la definición de los pacientes controladores, y los controladores elite, su evolución clinica e inmunológica, el tratamiento y las terapias disponibles en Colombia.
The Colombian Guide to Clinical Practice for HIV / AIDS Care in Adolescents and Adults, includes as first line of treatment the use of integrase inhibitors; however, there is no information to support the decision to treat elite control patients (EC). The definition of elite controller is confusing, because of the changes in definitions between studies, and it is unknown whether these recommendations apply to these patients in a similar way; and how should be systematic follow-up of elite controllers when antiretroviral therapy is initiated. Present paper is a bibliographic review of the available information on the definition of the controllers, and elite controllers its clinical and immunological evolution, the treatment and therapies available in Colombia.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Acquired Immunodeficiency Syndrome , HIV , Practice Guideline , Integrase Inhibitors , Clinical Evolution , Review , Infection Control , Aftercare , Integrases , InfectionsABSTRACT
Los inhibidores de transferencia de la cadena de integrasa (INSTI) son medicamentos cuyo mecanismo de acción consiste en bloquear el proceso de integración del ADN proviral al ADN del hospedero mediante la unión al sitio catalítico de la integrasa viral y de esta manera evitar su replicación. Actualmente se cuenta con la aprobación INSTI de primera y segunda generación, presentan similitud en su mecanismo de acción, cambios en su estructura que modifican su barrera genética, pero mantienen su perfil de seguridad y efectividad. Desde su aprobación en el año 2007, se han llevado a cabo múltiples estudios clínicos cuyos resultados han permitido avanzar en el conocimiento de su efectividad en diferentes escenarios clínicos; (pacientes naive, experimentados, esquemas de simplificación y profilaxis, así, como en el conocimiento de su perfil de mutaciones de resistencia). En el presente artículo se hizo una revisión de los miembros de esta familia de antirretrovirales (ARV).
Integrase strand transfer inhibitors (INSTI) are drugs whose mechanism of action consists of blocking the integration process of the proviral DNA to the host DNA by binding to the catalytic site of the viral integration and thus preventing its replication. Currently it has the approval of INSTI of first generation, two of second generation and in process of approval of a third of second generation. The two generations has similitude in its mechanisms of action, changes in its structures that modify its genetic barrier, but keeping his security and effectiveness profile. Since the approval of INSTI´s in 2007 to date, multiple clinical studies have been carried out, whose results have allowed us to advance in the knowledge of their effectiveness in different clinical scenarios; (naive patients, experienced patients, simplification and prophylaxis schemes, as well as in the knowledge of their profile of resistance mutations). In the present article, we made a review of the members of this family of antiretrovirals (ARV).
Subject(s)
Humans , Male , Female , DNA , Integrase Inhibitors , Family Characteristics , HIV , Review , Anti-Retroviral Agents , MutationABSTRACT
A quantitative structure-activity relationship (QSAR) study has been performed on integrase (IN) inhibition activity of a large series of N-methyl pyrimidones [Gardelli et al. (2007) J Med Chem 50, 4953-4975)] having varying heterocyclic ring substitution at 2-position of pyrimidone ring. The activity is found to be significantly correlated with surface tension and molar volume of the molecules. The whole series of compounds is divided into two subsets: a training set and a test set. A significant correlation is obtained for the training set, which is then used to predict the activity of compounds in the test set. The predicted activities of compounds in the test set are found to be very close to their observed activities. The predicting ability of the correlation obtained is judged by leave-one-out jackknife procedure. The correlation shows the effective role of the surface tension and molar volume of the molecules. From the correlation obtained, the integrase inhibition activities are predicted for some new prospective compounds.
Subject(s)
HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/pharmacology , Humans , Pyrimidinones/chemistry , Pyrimidinones/pharmacology , Quantitative Structure-Activity RelationshipABSTRACT
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
Subject(s)
Humans , Drug Resistance, Viral/genetics , HIV Infections/virology , HIV Integrase Inhibitors/pharmacology , HIV Integrase/genetics , HIV-1 , Virus Integration/drug effects , HIV Integrase/drug effects , HIV-1ABSTRACT
Integration is a critical step in the retroviral life cycle.HIV-1 integrase is involved in the integration of HIV DNA into host chromosomal DNA and appears to have no functionally equivalent in human cells.It has become an attractive and rational target for selective anti-AIDS therapy.A random linear heptapeptides phage display library was panned on the recombinant HIV-1 integrase protein.After five rounds of panning,13 positive phage clones were selected and sequenced.Two consensus peptides(TPSHSSR and HPERATL) were chemically synthesized.The non-radioactive ELISA-based HIV-1 integrase assay showed that the synthetic peptides TPSHSSR and HPERATL were able to inhibit the 3'cleavage or strand transfer activity of HIV-1 integrase to some extent(IC50=(54.56?5.18) ?mol/L,IC50=(28.29?1.32) ?mol/L,respectively) .These heptapeptides could be used for developing new anti-HIV drug candidates,as well as for structural studies of the three-dimensional structure of the entire integrase molecule.